NASDAQ · BRTX
Healthcare · Biotechnology
$2.24
Down-$0.35 (-15.62%)
Updated Oct 8, 2026, 9:54 PM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BRTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
BRTX closed at $2.24 after 21 trading sessions, down 18.25% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $2.30 | $2.30 | $2.05 | $2.24 | 38.68K |
| Oct 6, 2026 | $2.20 | $2.2895 | $2.135 | $2.27 | 79.66K |
| Oct 5, 2026 | $2.16 | $2.305 | $2.0096 | $2.24 | 85.22K |
| Oct 2, 2026 | $2.26 | $2.432 | $2.14 | $2.14 | 25.52K |
| Oct 1, 2026 | $2.28 | $2.4679 | $2.25 | $2.27 | 21.53K |
| Sep 30, 2026 | $2.26 | $2.39 | $2.26 | $2.33 | 24.95K |
| Sep 29, 2026 | $2.32 | $2.34 | $2.2601 | $2.33 | 15.08K |
| Sep 28, 2026 | $2.42 | $2.49 | $2.29 | $2.31 | 49.42K |
| Sep 25, 2026 | $2.55 | $2.68 | $2.445 | $2.55 | 29.44K |
| Sep 24, 2026 | $2.59 | $2.69 | $2.51 | $2.51 | 24.72K |
| Sep 23, 2026 | $2.61 | $2.8999 | $2.53 | $2.60 | 85.22K |
| Sep 22, 2026 | $2.72 | $2.9288 | $2.50 | $2.55 | 67.18K |
| Sep 21, 2026 | $2.70 | $2.75 | $2.68 | $2.71 | 26.91K |
| Sep 18, 2026 | $2.71 | $2.79 | $2.67 | $2.69 | 17.62K |
| Sep 17, 2026 | $2.66 | $2.7382 | $2.58 | $2.655 | 12.42K |
| Sep 16, 2026 | $2.62 | $2.67 | $2.55 | $2.55 | 15.5K |
| Sep 15, 2026 | $2.73 | $2.77 | $2.6202 | $2.64 | 9.66K |
| Sep 14, 2026 | $2.68 | $2.735 | $2.6578 | $2.70 | 7.2K |
| Sep 11, 2026 | $2.75 | $2.7795 | $2.63 | $2.67 | 11.65K |
| Sep 10, 2026 | $2.82 | $2.82 | $2.7013 | $2.76 | 27.77K |
| Sep 9, 2026 | $2.72 | $2.905 | $2.61 | $2.74 | 48.93K |
The latest Smart Investors Daily articles mentioning BRTX.
Company
Market Activity
Research & News
BRTX research
Company profile and research snapshot.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | Maxim Group | Hold | — |
| Aug 14, 2024 | Roth MKM | Buy | — |
| Jun 12, 2024 | Roth MKM | Buy | — |
| Aug 14, 2023 | Roth MKM | Buy | — |
| Dec 7, 2022 | Roth Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 8, 2026
Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX) stock moved
ChartMill · Feb 25, 2026
Which stocks have an unusual volume on Wednesday?
ChartMill · Feb 25, 2026
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Benzinga · Feb 25, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BRTX.
